𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Gene therapy for hepatic fibrosis—bringing treatment into the new millennium

✍ Scribed by Don C. Rockey

Publisher
John Wiley and Sons
Year
1999
Tongue
English
Weight
39 KB
Volume
30
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

✦ Synopsis

We eliminated type beta transforming growth factor (TGF-beta) signaling by adenovirus-mediated local expression of a dominant-negative type II TGF-beta receptor (AdCATbeta-TR) in the liver of rats treated with dimethylnitrosamine, a model of persistent liver fibrosis. In rats that received a single application of AdCATbeta-TR via the portal vein, liver fibrosis as assessed by histology and hydroxyproline content was markedly attenuated. All Ad-CATbeta-TR-treated rats remained alive, and their serum levels of hyaluronic acid and transaminases remained at low levels, whereas all the AdCATbeta-TR-untreated rats died of liver dysfunction. The results demonstrate that TGF-beta does play a central role in liver fibrogenesis and indicate clearly in a persistent fibrosis model that prevention of fibrosis by anti-TGF-beta intervention could be therapeutically useful.

📜 SIMILAR VOLUMES

Anti-chemokine therapy for the treatment
Anti-chemokine therapy for the treatment of hepatic fibrosis: An attractive approach
✍ Grant A. Ramm 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 631 KB

Activation of hepatic stellate cells in response to chronic inflammation represents a crucial step in the development of liver fibrosis. However, the molecules involved in the interaction between immune cells and stellate cells remain obscure. Herein, we identify the chemokine CCL5 (also known as RA